Shire PLC (SHPG) Expected to Announce Quarterly Sales of $4.02 Billion
Wall Street brokerages expect Shire PLC (NASDAQ:SHPG) to post sales of $4.02 billion for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Shire’s earnings. The lowest sales estimate is $3.96 billion and the highest is $4.07 billion. Shire reported sales of $3.81 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 5.5%. The firm is expected to report its next quarterly earnings results on Thursday, February 15th.
According to Zacks, analysts expect that Shire will report full-year sales of $4.02 billion for the current year, with estimates ranging from $14.89 billion to $15.10 billion. For the next year, analysts anticipate that the company will post sales of $15.82 billion per share, with estimates ranging from $15.35 billion to $16.58 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Shire.
Shire (NASDAQ:SHPG) last posted its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.64 by $0.17. Shire had a return on equity of 14.41% and a net margin of 10.95%. The firm had revenue of $3.70 billion during the quarter. During the same period in the prior year, the company posted $3.17 earnings per share. The firm’s revenue for the quarter was up 7.1% compared to the same quarter last year.
Several institutional investors and hedge funds have recently modified their holdings of the business. Harding Loevner LP increased its stake in shares of Shire by 18,894.4% in the 3rd quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock worth $20,354,000 after acquiring an additional 126,865,607 shares during the last quarter. Maverick Capital Ltd. increased its stake in shares of Shire by 19.9% in the 2nd quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock worth $320,969,000 after acquiring an additional 322,610 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of Shire by 35.3% in the 3rd quarter. Janus Henderson Group PLC now owns 1,740,973 shares of the biopharmaceutical company’s stock worth $266,613,000 after acquiring an additional 454,092 shares during the last quarter. Glenview Capital Management LLC increased its stake in shares of Shire by 69.7% in the 2nd quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock worth $284,756,000 after acquiring an additional 707,500 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in shares of Shire by 6.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,606,342 shares of the biopharmaceutical company’s stock worth $245,997,000 after acquiring an additional 96,115 shares during the last quarter. 20.27% of the stock is owned by institutional investors and hedge funds.
Shire (NASDAQ:SHPG) opened at $148.50 on Tuesday. Shire has a 52 week low of $137.17 and a 52 week high of $192.15. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $44,860.00, a price-to-earnings ratio of 10.18, a P/E/G ratio of 0.82 and a beta of 1.59.
TRADEMARK VIOLATION WARNING: “Shire PLC (SHPG) Expected to Announce Quarterly Sales of $4.02 Billion” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/12/shire-plc-shpg-expected-to-announce-quarterly-sales-of-4-02-billion.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.